Deulorlatinib clinical trials
Also written TGRX-326.
How each study uses deulorlatinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- TGRX-326
- 4
Studies by the year they started
5 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 2 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Shenzhen TargetRx, Inc. (5)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses deulorlatinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 2Shenzhen TargetRx, Inc.NCT05955391Written as TGRX-326
- TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 3Shenzhen TargetRx, Inc.NCT06082635Written as TGRX-326
- TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 1Shenzhen TargetRx, Inc.NCT05441956Written as TGRX-326
- TGRX-326 Pharmacokinetic Mass BalanceCompletedPhase 1Shenzhen TargetRx, Inc.NCT06438367Written as [14C]TGRX-326
- TGRX-326 Pharmacokinetic Drug InteractionCompletedPhase 1Shenzhen TargetRx, Inc.NCT06294561Written as Itraconazole+TGRX-326
Codes
What other systems call deulorlatinib · ClinicalTrials.gg INT015514
- UNII (FDA) 7PW3UT8C9BDEULORLATINIBOne source FDA
- NCI Thesaurus C189066DeulorlatinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 7PW3UT8C9B | DEULORLATINIB | One source FDA |
| NCI Thesaurus | C189066 | Deulorlatinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.